ストックスクリーナーアプリを入手
1.60
2.15%
-0.03
前日終値:
$1.63
開ける：
$1.66
24時間の取引高:
901.94K
Relative Volume:
0.18
時価総額：
$237.98M
収益：
-
当期純損益:
$-14.07M
株価収益率:
-0.1144
EPS:
-13.99
ネットキャッシュフロー:
$-12.56M
1週間 パフォーマンス:
-7.80%
1か月 パフォーマンス:
-15.61%
6か月 パフォーマンス:
+121.56%
1年 パフォーマンス:
+62.76%
1日の値動き範囲:
$1.58
$1.6697
1週間の範囲:
$1.58
$1.77
52週間の値動き範囲:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
名前
Palisade Bio Inc
セクター
電話
(858) 704-4900
住所
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.595 | 243.20M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.81 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.48 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
848.19 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.92 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
359.18 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | 開始されました | B. Riley Securities | Buy |
| 2025-12-29 | 開始されました | Piper Sandler | Overweight |
Palisade Bio Inc (PALI) 最新ニュース
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest - Defense World
Palisade Bio appoints IBD expert to clinical advisory board - Investing.com
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - Bitget
Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Can Palisade Bio Inc. (7NS0) stock resist broad market declinesPortfolio Risk Report & Precise Trade Entry Recommendations - mfd.ru
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com Australia
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com
Palisade Bio CEO Finley sells $6818 in shares By Investing.com - Investing.com Canada
Palisade Bio CEO Finley sells $6818 in shares - Investing.com Nigeria
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Palisade Bio Inc. maintain sales growthJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewswire
Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Aug Shorts: Will Palisade Bio Inc outperform its industry peers2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Can Palisade Bio Inc maintain sales growth2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
Palisade Bio appoints two IBD experts to clinical advisory board By Investing.com - Investing.com South Africa
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board - markets.businessinsider.com
Palisade Bio appoints two IBD experts to clinical advisory board - Investing.com
Two IBD leaders join Palisade Bio push on PALI-2108 for colitis and Crohn's - stocktitan.net
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Risk Analysis: Will Belpointe PREP LLC benefit from geopolitical trendsEarnings Overview Report & Stepwise Swing Trade Plans - baoquankhu1.vn
MACD Signal: Does Palisade Bio Inc have declining or rising EPSWeekly Profit Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Portfolio Update: Is CINGW a potential multi baggerInflation Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December - MarketBeat
Published on: 2026-01-19 10:30:24 - baoquankhu1.vn
Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn
Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com Nigeria
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com India
Palisade Bio Inc (PALI) 財務データ
収益
当期純利益
現金流量
EPS
Palisade Bio Inc (PALI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
0.66%
0.10%
大文字化:
|
ボリューム (24 時間):